Carboplatin injection should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Appropriate management of therapy and complications is possible only when adequate treatment facilities are readily available.
Bone marrow suppression is dose related and may be severe, resulting in infection and/or bleeding. Anemia may be cumulative and may require transfusion support. Vomiting is another frequent drug related side effect.
Anaphylactic-like reactions to carboplatin have been reported and may occur within minutes of carboplatin injection administration. Epinephrine, corticosteroids, and antihistamines have been employed to alleviate symptoms.
Carboplatin injection is supplied as a sterile, pyrogen-free, 10 mg/mL aqueous solution of carboplatin, USP. Carboplatin, USP is a platinum coordination compound.
Initial Treatment of Advanced Ovarian Carcinoma
Carboplatin injection is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents. One established combination regimen consists of carboplatin and cyclophosphamide. Two randomized controlled studies conducted by the NCIC and SWOG with carboplatin versus cisplatin, both in combination with cyclophosphamide, have demonstrated equivalent overall survival between the two groups (see
Secondary Treatment of Advanced Ovarian Carcinoma
Carboplatin injection is indicated for the palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy, including patients who have been previously treated with cisplatin.
Within the group of patients previously treated with cisplatin, those who have developed progressive disease while receiving cisplatin therapy may have a decreased response rate.
Media Articles Related to Carboplatin
African American women with ovarian cancer - can obesity mask early symptoms?
Source: Obesity / Weight Loss / Fitness News From Medical News Today [2016.04.29]
African American women with ovarian cancer are more likely to die from the disease than are White women and they are also much more likely to be obese.
Gene Tests May Help Predict Outcomes in Advanced Ovarian Cancer
Source: MedicineNet Ovarian Cancer Specialty [2016.03.21]
Title: Gene Tests May Help Predict Outcomes in Advanced Ovarian Cancer
Category: Health News
Created: 3/19/2016 12:00:00 AM
Last Editorial Review: 3/21/2016 12:00:00 AM
Ovarian Cancer Is More Than One Disease: Report
Source: MedicineNet Ovarian Cancer Specialty [2016.03.03]
Title: Ovarian Cancer Is More Than One Disease: Report
Category: Health News
Created: 3/2/2016 12:00:00 AM
Last Editorial Review: 3/3/2016 12:00:00 AM
Source: MedicineNet Hormone Therapy Specialty [2016.01.28]
Title: Ovarian Cancer
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 1/28/2016 12:00:00 AM
Annual Blood Test Might Help Prevent Deaths From Ovarian Cancer
Source: MedicineNet Ovarian Cancer Specialty [2015.12.17]
Title: Annual Blood Test Might Help Prevent Deaths From Ovarian Cancer
Category: Health News
Created: 12/17/2015 12:00:00 AM
Last Editorial Review: 12/17/2015 12:00:00 AM
Published Studies Related to Carboplatin
In vivo intraocular distribution and safety of periocular nanoparticle
carboplatin for treatment of advanced retinoblastoma in humans. 
DESIGN: Prospective, interventional, comparative case series... CONCLUSION: Results may indicate an increased facilitated trans-scleral transport
Weekly AUC2 carboplatin in acquired platinum-resistant ovarian cancer with or
without oral phenoxodiol, a sensitizer of platinum cytotoxicity: the phase III
OVATURE multicenter randomized study. 
potential, when combined with weekly AUC2-carboplatin in PROC patients... CONCLUSIONS: Orally delivered PXD showed no evidence of clinical activity, when
Randomized, phase II, placebo-controlled, double-blind study with and without
enzastaurin in combination with paclitaxel and carboplatin as first-line
treatment followed by maintenance treatment in advanced ovarian cancer. 
diagnosed advanced ovarian cancer... CONCLUSION: The PCE combination increased PFS, but it was not significantly
Phase III trial of carboplatin and paclitaxel with or without sorafenib in
metastatic melanoma. 
metastatic melanoma... CONCLUSION: Sorafenib does not improve OS when given in combination with CP for
A Phase II, randomized, double-blind study of zibotentan (ZD4054) in combination
with carboplatin/paclitaxel versus placebo in combination with
carboplatin/paclitaxel in patients with advanced ovarian cancer sensitive to
platinum-based chemotherapy (AGO-OVAR 2.14). 
xenograft models of human ovarian cancer... CONCLUSIONS: Zibotentan 10mg/day plus carboplatin and paclitaxel did not result
Clinical Trials Related to Carboplatin
Trientine and Carboplatin in Advanced Malignancies [Completed]
The goal of this clinical research study is to find the highest tolerable dose of the
combination of trientine and carboplatin that can be given to patients with advanced cancer.
The safety of this drug combination will also be studied.
BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid Tumors [Recruiting]
The purpose of this study is to find out the good and bad effects that occur when BKM120 is
added to standard chemotherapy with carboplatin and paclitaxel.
Heated Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Peritoneal Cancer [Recruiting]
This phase I trial studies the side effects and best dose of heated carboplatin given into
the abdomen at the time of surgery in treating patients with stage II-IV ovarian, fallopian
tube, or peritoneal cancer. Drugs used in chemotherapy, such as carboplatin, work in
different ways to stop the growth of tumor cells, either by killing the cells, by stopping
them from dividing, or by stopping them from spreading. Heating oxaliplatin and infusing it
directly into the area around the tumor during surgery may kill more tumor cells.
Study Of Intraductal Carboplatin In Women With Ductal Carcinoma In Situ (DCIS) [Recruiting]
The primary objective of this study is to compare the safety of 100 mg carboplatin
administered intraductally once on Day 1 or twice on Days 1 and 15 in women with ductal
carcinoma in situ (DCIS) undergoing surgical management 2 to 4 weeks following the Day 15
intraductal infusion. Secondary objectives are to characterize the biologic and clinical
effects with respect to: pharmacokinetics, extent of disease on MRI and mammogram,
histopathological assessment of DCIS, and biomarker measurement of Ki-67, TUNEL and G-actin.
Open-label Phase 1b Study of ARQ 092 in Combination With Carboplatin Plus Paclitaxel [Recruiting]
An Open-label Phase 1b Study of ARQ 092 in Combination with Carboplatin Plus Paclitaxel in
Subjects with Selected Solid Tumors
Reports of Suspected Carboplatin Side Effects
Febrile Neutropenia (206),
Pyrexia (141), more >>
Page last updated: 2016-04-29